EA201401271A1 - Фармацевтическая композиция, содержащая (1r,4r)-6'-фтор-n,n-диметил-4-фенил-4',9'-дигидро-3'h-спиро[циклогексан-1,1'-пирано[3,4,b]индол]-4-амин и антиконвульсант - Google Patents
Фармацевтическая композиция, содержащая (1r,4r)-6'-фтор-n,n-диметил-4-фенил-4',9'-дигидро-3'h-спиро[циклогексан-1,1'-пирано[3,4,b]индол]-4-амин и антиконвульсантInfo
- Publication number
- EA201401271A1 EA201401271A1 EA201401271A EA201401271A EA201401271A1 EA 201401271 A1 EA201401271 A1 EA 201401271A1 EA 201401271 A EA201401271 A EA 201401271A EA 201401271 A EA201401271 A EA 201401271A EA 201401271 A1 EA201401271 A1 EA 201401271A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- diamide
- spiro
- dihydro
- fluoro
- dimethyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Изобретение относится к фармацевтической композиции, содержащей первый фармакологически активный ингредиент, выбранный из (1R,4R)-6'-фтор-N,N-диметил-4-фенил-4',9'-дигидро-3'Н-спиро[циклогексан-1,1'-пирано-[3,4,b]индол]-4-амина и его физиологически приемлемых солей, и второй фармакологически активный ингредиент, который представляет собой антиконвульсант, выбранный из группы, которая включает ретигабин, ламотригин, лакосамид, леветирацетам, карбамазепин, сультиам, фенацемид, фельбамат, топирамат, фенетурид, бриварацетам, селектрацетам, зонисамид, стирипентол, бекламид, мексилетин, ральфинамид, метилфенобарбитал, фенобарбитал, примидон, барбексаклон, метарбитал, этотоин, фенитоин, амино(дифенилгидантоин) валериановую кислоту, мефенитоин, фосфенитоин, параметадион, триметадион, этадион, этосуксимид, фенсуксимид, месуксимид, клоназепам, лоразепам, диазепам, клобазам, окскарбазепин, эсликарбазепин, руфинамид, вальпроевую кислоту, вальпромид, аминомасляную кислоту, прогабид, тиагабин, и их физиологически приемлемые соли.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12003898 | 2012-05-18 | ||
EP13159330 | 2013-03-15 | ||
PCT/EP2013/001471 WO2013170972A1 (en) | 2012-05-18 | 2013-05-16 | Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano [3,4,b]indol]-4-amine and an anticonvulsant |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201401271A1 true EA201401271A1 (ru) | 2015-05-29 |
EA029767B1 EA029767B1 (ru) | 2018-05-31 |
Family
ID=48446244
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201401271A EA029767B1 (ru) | 2012-05-18 | 2013-05-16 | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ (1r,4r)-6'-ФТОР-N,N-ДИМЕТИЛ-4-ФЕНИЛ-4',9'-ДИГИДРО -3'H-СПИРО[ЦИКЛОГЕКСАН-1,1'-ПИРАНО[3,4,b]ИНДОЛ]-4-АМИН И АНТИКОНВУЛЬСАНТ |
Country Status (21)
Country | Link |
---|---|
US (1) | US9345689B2 (ru) |
EP (1) | EP2852384B1 (ru) |
JP (1) | JP6116679B2 (ru) |
CN (1) | CN104284656A (ru) |
AU (1) | AU2013262078B2 (ru) |
CA (1) | CA2873871A1 (ru) |
CY (1) | CY1118634T1 (ru) |
DK (1) | DK2852384T3 (ru) |
EA (1) | EA029767B1 (ru) |
ES (1) | ES2624220T3 (ru) |
HK (1) | HK1204937A1 (ru) |
HR (1) | HRP20170517T1 (ru) |
HU (1) | HUE031984T2 (ru) |
IL (1) | IL235654A (ru) |
LT (1) | LT2852384T (ru) |
MX (1) | MX353177B (ru) |
PL (1) | PL2852384T3 (ru) |
PT (1) | PT2852384T (ru) |
RS (1) | RS55905B1 (ru) |
SI (1) | SI2852384T1 (ru) |
WO (1) | WO2013170972A1 (ru) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6673924B2 (ja) | 2015-01-23 | 2020-03-25 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 肝機能障害および/または腎機能障害を有する対象における疼痛を治療するためのセブラノパドール |
EP3419621A4 (en) * | 2016-02-26 | 2019-10-30 | The Johns Hopkins University | PHARMACOLOGICAL MODULATORS OF NAV1.1 VOLTAGE-CONTROLLED SODIUM CHANNELS ASSOCIATED WITH MECHANICAL PAIN |
US20190125725A1 (en) * | 2016-05-12 | 2019-05-02 | Jubilant Generics Limited | Pharmaceutical compositions comprising brivaracetam |
AU2017371467B2 (en) * | 2016-12-06 | 2023-06-01 | Jan Marius KEPPEL HESSELINK | Topical phenytoin for use in the treatment of peripheral neuropathic pain |
EP3826610A4 (en) * | 2018-07-24 | 2022-05-04 | Zenvision Pharma LLP | SYSTEM FOR NASAL DRUG DELIVERY OF BRIVARACETAM OR A SALT THEREOF |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4389393A (en) | 1982-03-26 | 1983-06-21 | Forest Laboratories, Inc. | Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose |
US4783337A (en) | 1983-05-11 | 1988-11-08 | Alza Corporation | Osmotic system comprising plurality of members for dispensing drug |
US4612008A (en) | 1983-05-11 | 1986-09-16 | Alza Corporation | Osmotic device with dual thermodynamic activity |
US4765989A (en) | 1983-05-11 | 1988-08-23 | Alza Corporation | Osmotic device for administering certain drugs |
US5708035A (en) | 1991-02-04 | 1998-01-13 | Sepracor Inc. | Methods of use and compositions of R(-) fluoxetine |
US5472711A (en) | 1992-07-30 | 1995-12-05 | Edward Mendell Co., Inc. | Agglomerated hydrophilic complexes with multi-phasic release characteristics |
US5330761A (en) | 1993-01-29 | 1994-07-19 | Edward Mendell Co. Inc. | Bioadhesive tablet for non-systemic use products |
US5455046A (en) | 1993-09-09 | 1995-10-03 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
US5399362A (en) | 1994-04-25 | 1995-03-21 | Edward Mendell Co., Inc. | Once-a-day metoprolol oral dosage form |
US20030056896A1 (en) * | 1995-05-12 | 2003-03-27 | Frank Jao | Effective therapy for epilepsies |
US6117900A (en) | 1999-09-27 | 2000-09-12 | Asta Medica Aktiengesellschaft | Use of retigabine for the treatment of neuropathic pain |
US8637512B2 (en) | 2002-07-29 | 2014-01-28 | Glaxo Group Limited | Formulations and method of treatment |
DE10252667A1 (de) * | 2002-11-11 | 2004-05-27 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
PT1567164E (pt) | 2002-11-26 | 2009-03-31 | Alexza Pharmaceuticals Inc | Utilização de loxapina para o fabrico de um medicamento para o tratamento da dor |
US20040222123A1 (en) * | 2003-05-06 | 2004-11-11 | Barr Laboratories, Inc. | Kit for pharmaceuticals |
CN1245379C (zh) | 2003-10-30 | 2006-03-15 | 曹桂东 | 加巴喷丁的制法 |
DE10360792A1 (de) | 2003-12-23 | 2005-07-28 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
GB0412878D0 (en) | 2004-06-09 | 2004-07-14 | Pfizer Ltd | Use |
AU2005256944A1 (en) | 2004-06-09 | 2006-01-05 | Pfizer Inc. | Use of reboxetine for the treatment of pain |
US8093408B2 (en) | 2005-06-21 | 2012-01-10 | The Company Wockhardt | Antidepressant oral pharmaceutical compositions |
US20080014264A1 (en) | 2006-07-13 | 2008-01-17 | Ucb, S.A. | Novel pharmaceutical compositions comprising levetiracetam |
DE102006046745A1 (de) | 2006-09-29 | 2008-04-03 | Grünenthal GmbH | Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz |
JP2008106028A (ja) * | 2006-10-26 | 2008-05-08 | Boehringer Ingelheim Internatl Gmbh | 慢性疼痛の治療におけるフリバンセリンの使用 |
US20080153874A1 (en) | 2006-12-22 | 2008-06-26 | Allergan Inc. | Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain |
WO2008108639A1 (en) | 2007-03-08 | 2008-09-12 | Avantium Holding B.V. | Co-crystalline forms of carbamazepine |
EP1977744A1 (en) | 2007-04-03 | 2008-10-08 | Chemo Ibérica, S.A. | Polymorphic Form alpha of (S)-Pregabalin and process for its preparation |
DK2244703T3 (da) * | 2007-12-21 | 2011-12-05 | Horizon Pharma Ag | Lægemiddel og fremstillingen og anvendelse deraf i behandlingen af smertefulde neuropatier |
EP2297092A1 (en) | 2008-05-28 | 2011-03-23 | Pliva Hrvatska D.O.O. | Polymorphic and amorphous forms of lacosamide and amorphous compositions |
PE20110291A1 (es) * | 2008-09-05 | 2011-06-04 | Gruenenthal Chemie | Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico |
DE102009013613A1 (de) | 2009-03-17 | 2010-09-23 | Ratiopharm Gmbh | Trockenverarbeitung von Retigabin |
NZ605887A (en) * | 2010-08-04 | 2014-08-29 | Gruenenthal Gmbh | Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of neuropathic pain |
CA2804077C (en) * | 2010-08-04 | 2018-09-11 | Gruenenthal Gmbh | Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine |
CA2802767C (en) * | 2010-08-04 | 2019-08-13 | Gruenenthal Gmbh | Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine |
-
2013
- 2013-05-13 US US13/892,751 patent/US9345689B2/en active Active
- 2013-05-16 PL PL13723004T patent/PL2852384T3/pl unknown
- 2013-05-16 RS RS20170381A patent/RS55905B1/sr unknown
- 2013-05-16 AU AU2013262078A patent/AU2013262078B2/en not_active Ceased
- 2013-05-16 MX MX2014013179A patent/MX353177B/es active IP Right Grant
- 2013-05-16 EP EP13723004.1A patent/EP2852384B1/en active Active
- 2013-05-16 WO PCT/EP2013/001471 patent/WO2013170972A1/en active Application Filing
- 2013-05-16 CN CN201380025637.XA patent/CN104284656A/zh active Pending
- 2013-05-16 LT LTEP13723004.1T patent/LT2852384T/lt unknown
- 2013-05-16 JP JP2015511958A patent/JP6116679B2/ja active Active
- 2013-05-16 EA EA201401271A patent/EA029767B1/ru not_active IP Right Cessation
- 2013-05-16 DK DK13723004.1T patent/DK2852384T3/en active
- 2013-05-16 HU HUE13723004A patent/HUE031984T2/en unknown
- 2013-05-16 CA CA2873871A patent/CA2873871A1/en not_active Abandoned
- 2013-05-16 ES ES13723004.1T patent/ES2624220T3/es active Active
- 2013-05-16 SI SI201330569A patent/SI2852384T1/sl unknown
- 2013-05-16 PT PT137230041T patent/PT2852384T/pt unknown
-
2014
- 2014-11-12 IL IL235654A patent/IL235654A/en active IP Right Grant
-
2015
- 2015-06-11 HK HK15105568.4A patent/HK1204937A1/xx not_active IP Right Cessation
-
2017
- 2017-02-15 CY CY20171100205T patent/CY1118634T1/el unknown
- 2017-03-30 HR HRP20170517TT patent/HRP20170517T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
JP6116679B2 (ja) | 2017-04-19 |
HK1204937A1 (en) | 2015-12-11 |
MX353177B (es) | 2018-01-05 |
CY1118634T1 (el) | 2017-07-12 |
HUE031984T2 (en) | 2017-08-28 |
LT2852384T (lt) | 2017-04-25 |
DK2852384T3 (en) | 2017-05-08 |
CN104284656A (zh) | 2015-01-14 |
AU2013262078A1 (en) | 2015-01-22 |
ES2624220T3 (es) | 2017-07-13 |
EP2852384B1 (en) | 2017-02-01 |
WO2013170972A1 (en) | 2013-11-21 |
MX2014013179A (es) | 2015-01-19 |
PL2852384T3 (pl) | 2017-09-29 |
HRP20170517T1 (hr) | 2017-06-02 |
CA2873871A1 (en) | 2013-11-21 |
EA029767B1 (ru) | 2018-05-31 |
PT2852384T (pt) | 2017-05-10 |
EP2852384A1 (en) | 2015-04-01 |
IL235654A (en) | 2017-07-31 |
SI2852384T1 (sl) | 2017-04-26 |
IL235654A0 (en) | 2015-01-29 |
RS55905B1 (sr) | 2017-09-29 |
AU2013262078B2 (en) | 2017-10-26 |
US20130317009A1 (en) | 2013-11-28 |
US9345689B2 (en) | 2016-05-24 |
JP2015516452A (ja) | 2015-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201401271A1 (ru) | Фармацевтическая композиция, содержащая (1r,4r)-6'-фтор-n,n-диметил-4-фенил-4',9'-дигидро-3'h-спиро[циклогексан-1,1'-пирано[3,4,b]индол]-4-амин и антиконвульсант | |
ATE551328T1 (de) | Neuartige 5-substituierte hydantoine | |
EA200870599A1 (ru) | Стабильные препараты лаквинимода | |
EA201370066A1 (ru) | Модуляторы эстрогеновых рецепторов и их применение | |
AR026087A1 (es) | Aminoacidos biciclicos como agentes farmaceuticos. | |
EA201290032A1 (ru) | Синтез и применение вилдаглиптина для получения лекарственных форм | |
BRPI0409977A (pt) | derivados de aminopropanol como moduladores de receptores esfingosina-1-fosfato | |
EA200100748A1 (ru) | Ингибиторы обратного захвата моноаминов для лечения расстройств цнс | |
EA200970428A1 (ru) | [f-18]-меченая l-глутаминовая кислота, [f-18]-меченый l-глутамин, их производные и их применение, а также способ их получения | |
CO6351689A2 (es) | Formulaciones farmaceuticas que contienen ligandos de receptores de dopamina | |
CL2009000464A1 (es) | Compuestos derivados de 3-(n-(azetidin-3-il)metanosulfonilamino)benzamida, actuan en los receptores cannabinoides cb1; procedimiento para prepararlos; composici0n farmaceutica y su uso para tratar o prevenir trastornos psiquiatricos, trastornos cognitivos, enfermedades neurodegenerativas, trastornos del metabolismo, dolor. | |
EA201001766A1 (ru) | Новые[f-18]-меченые производные l-глутаминовой кислоты и l-глутамина (i), их применение, а также способ их получения | |
CY1120756T1 (el) | Διαλυτοποιημενη φαρμακοτεχνικη μορφη καψουλας [(1s)-1-{[(2s,4r)-4-(7-xλωpo-4-meθοξυ-ισοκινολιν-1-υλοξυ)-2-({(1r,2s)-1-[(κυκλοπροπυλσουλφονυλ)καρβαμοϋλ]-2-αιθενυλκυκλοπροπυλ}καρβαμοϋλ)πυρρολιδιν-1-υλ]καρβονυλ}-2,2-διμεθυλπροπυλ]καρβαμικου 1,1-διμεθυλαιθυλιου | |
CL2009001414A1 (es) | Procedimiento de sintesis de 7,8-dimetoxi-1,3-dihidro-2h-3-benzazepin-2-ona sin aislacion de compuestos intermediarios; util para la sintesis de ivabradina. | |
EA201291169A1 (ru) | Промежуточные соединения саксаглиптина, полиморфы саксаглиптина и способы их получения | |
EA201270087A1 (ru) | Твердые фармацевтические композиции с фиксированной дозой, содержащие ирбесартан и амлодипин, их получение и их терапевтическое применение | |
EA201691869A1 (ru) | Стабильная комбинированная фармацевтическая композиция | |
EA201001353A1 (ru) | Гидробромид ивабрадина | |
EA201400120A1 (ru) | Кристаллический (1r,4r)-6'-фтор-n,n-диметил-4-фенил-4',9'-дигидро-3'н-спиро[циклогексан-1,1'-пирано[3,4,в]индол]-4-амин | |
EA201390950A1 (ru) | Гомогенные фармацевтические пероральные лекарственные формы, содержащие лерканидипин и эналаприл или их фармацетически приемлемые соли совместно с органической кислотой | |
EA201071309A1 (ru) | Твердая фармацевтическая композиция | |
EA201290817A1 (ru) | Твердые фармацевтические композиции рамиприла и безилата амлодипина и их получение | |
TR201820411T4 (tr) | Rasetam ve karnitin içeren farmasötik bileşim ve bunun hazırlanış süreci. | |
ATE536342T1 (de) | Neue carbamoylglycinderivate | |
EA201100104A1 (ru) | Фармацевтическая композиция, содержащая статин |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM |
|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): RU |